Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (280)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (5)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 161 to 170 of 280
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Oral semaglutide for managing overweight and obesity [ID6188]
Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472
Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Technology appraisal guidance
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865
Technology appraisal guidance
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467
Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
Technology appraisal guidance
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over TSID 12047
Technology appraisal guidance
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021
Technology appraisal guidance
Previous page
1
…
15
16
Current page
17
18
19
…
28
Page
17
of
28
Next page
Results per page
10
25
50
All
Back to top